Category Archives: Biotechnology

NEW YORK, NY--(Marketwire - Oct 15, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to the industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Amicus Therapeutics, Inc. ( NASDAQ : FOLD ) and Osiris Therapeutics, Inc. ( NASDAQ : OSIR ).

Access to the full company reports can be found at: http://www.FiveStarEquities.com/FOLD http://www.FiveStarEquities.com/OSIR

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare diseases. Shares of the company soared last Thursday after it reported positive preliminary results from an ongoing Phase 2 study for the treatment of people with Pompe disease.

Osiris Therapeutics, having developed the world's first approved stem cell drug Prochymal, is the leading stem cell company. The company is focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets. The company recently reported that Swissmedic has invoked rapid authorization procedures for the Prochymal review.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

See original here:
Biotech Industry Look to Benefit From New Act Designed to Promote R&D Joint Ventures

NEW YORK, NY--(Marketwire - Oct 1, 2012) - The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on StemCells, Inc. ( NASDAQ : STEM ) and Neuralstem, Inc. ( NYSE : CUR ).

Access to the full company reports can be found at: http://www.FiveStarEquities.com/STEM http://www.FiveStarEquities.com/CUR

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries." BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. Shares of the company surged last Thursday after it reported it has enrolled its first patient in a Phase I/II clinical trial for the treatment of a chronic spinal cord injury.

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. The company recently reported it has been approved to commence an ischemic stroke trial in China.

Five Star Equities provides Market Research focused on equities hat offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.FiveStarEquities.com/disclaimer

Excerpt from:
Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announces Therapeutic Workshops on Cancer stem cell therapy, kinase drugs, and ultra rare diseases planned for the upcoming BIO Investor Forum. Hosted by BIO, the 11th annual event will take place at the Palace Hotel on October 9-10 in San Francisco, Calif.

This years Therapeutic Workshops will address some of the most exciting therapeutic advances for the biotech industry. We have worked very closely with this years esteemed Advisory Committee to identify topics that will engage investors and industry alike, said Alan Eisenberg, executive vice president, Emerging Companies & Business Developmentat BIO.

Therapeutic Workshops will feature senior-level industry executives, scientific officers and leading clinical experts that represent innovative investment opportunities in the biotech industry.

Therapeutic Workshops include:

The BIO Investor Forum features public and venture-stage company presentations, expert-led, business roundtables, one-on-one investor meetings and networking opportunities.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Advance media registration is available here. Registration is complimentary for credentialed members of the media and qualified investors.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including Supporting Bank Stifel, Nicolaus & Company. BIO Double Helix and Helix Sponsors include Abbott Biotech Ventures, Amgen Ventures, Baxter Ventures, J&J Development Corporation, MedImmune Ventures, GlaxoSmithKline, Merck and Pfizer.

About BIO

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIO produces BIOtechNOW, an online portal and monthly newsletter chronicling innovations transforming our world. Subscribe to BIOtechNOW.

View original post here:
BIO Announces Therapeutic Workshops for 11th Annual BIO Investor Forum

SAN DIEGO--(BUSINESS WIRE)--

This week in the journal Scientific Reports (Nature Publishing Group), scientists from Allele Biotechnology describe an important advance in the generation of stem cells capable of producing all the different tissues of the human body. In an article entitled Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA, Alleles scientists present the fastest and safest method yet for converting ordinary human skin cells into induced pluripotent stem cells (iPSCs).

The scientific efforts were led by Dr. Luigi Warren, whose pioneering work on footprint-free reprogramming using messenger RNA was the foundation for Alleles breakthrough. Through the united efforts of Dr. Warren and the scientists at Allele Biotechnology, his technique was re-engineered to increase cell conversion efficiency and eliminate any use of potentially unsafe reagents, while substantially reducing the time and effort needed to make stem cells. Dr. Warren believes that because of its advantages this technology should become the method of choice for iPSC cell banking.

According to Dr. Jiwu Wang, corresponding author on the paper and CEO of Allele Biotechnology, This advance in stem cell derivation will enable both fundamental scientific research and clinical applications which has been the mission of Allele Biotechnology from its inception.

Allele Biotechnology and Pharmaceuticals Inc. is a San Diego-based biotechnology company that was established in 1999 by Dr. Jiwu Wang and colleagues. A research based company specializing in the fields of RNAi, stem cells, viral expression, camelid antibodies and fluorescent proteins; Allele Biotechnology has always striven to offer products and services at the cutting edge of research.

Follow this link:
Allele Biotechnology Announces New Advance in Production of Human Stem Cells

NEW YORK, NY--(Marketwire -08/03/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) are both up 31 percent for the year, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Osiris Therapeutics, Inc. (OSIR) and Pluristem Therapeutics Inc. (PSTI).

Access to the full company reports can be found at: http://www.ParagonReport.com/OSIR http://www.ParagonReport.com/PSTI

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Osiris Therapeutics is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris' stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.

Pluristem Therapeutics is a leading developer of placenta-based cell therapies. The company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic disease. Shares of the company have gained 40 percent in the last month.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Go here to read the rest:
Osiris Therapeutics and Pluristem Therapeutics Showing Impressive Growth as Biotech Industry Thrives in 2012

NEW YORK, NY--(Marketwire -07/24/12)- The Biotechnology Industry has been soaring in 2012 as companies -- both large and small -- have shown impressive growth. The SPDR S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech Index ETF (FBT) year-to-date are up 38 percent and 37 percent, respectively, outperforming the broader market by a wide margin. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on StemCells, Inc. (STEM) and Keryx Biopharmaceuticals (KERX).

Access to the full company reports can be found at:

http://www.ParagonReport.com/STEM http://www.ParagonReport.com/KERX

Despite having to negotiate a more challenging regulation process biotech companies have continued to show investors strong gains in 2012. The FDA Amendments Act of 2007 forced regulators to increase standards for approvals of new drugs, introducing mandatory risk evaluation and mitigation strategies. According to a Pharmaceuticals & Biotechnology report from IMAP, several pharmaceutical firms have altered their drug portfolios from primary care driven blockbusters towards specialties such as oncology, immunology and inflammation, where the medical need is "so high that prices are more easily accepted by the regulators."

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

StemCells is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The company recently announced preclinical data demonstrating that its proprietary human neural stem cells restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease. Shares of the company have soared nearly 90 percent this year.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Shares of the company have rebounded nearly 50 percent over the last three months.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.paragonreport.com/disclaimer

Excerpt from:
StemCells and Keryx Biopharmaceuticals Showing Strong Gains as Biotechnology Industry Soars in 2012

CEDAR KNOLLS, NJ--(Marketwire -06/27/12)- MYOS Corporation (MYOS), a company focused on the discovery, development and commercialization of muscle health and performance therapeutic products, today announced that it has appointed Sol J. Barer, Ph.D., to Chair its Scientific Advisory Board.

Dr. Barer is the former Chairman and Chief Executive Officer of Celgene Corporation, a leading global biotechnology company specializing in cancer, hematologic and immunologic pharmaceuticals. He retired last year from a successful Celgene career where he served as Chairman from 2006 to 2011, and Chief Executive Officer from 2006 to 2010. Prior, he served as Celgene President and Chief Operating Officer since 1993, and 1994, respectively.

Dr. Barer serves as a director of a number of corporate and not-for-profit Boards.

Commenting on his appointment to Chairman of the MYOS Scientific Advisory Board, Dr. Barer said, "The nascent field of muscle biology and the technologies which maximize the health and performance of this organ system represents significant, previously untapped potential. MYOS is positioning itself to play an important and meaningful role in the discovery, development and clinical use of new products which will improve the health and performance of an organ system which we often forget is so vital to the quality of our lives.

"I am especially pleased to serve in this position so early in the Company's development, and to collaborate with its Board and growing management team," he added.

Commenting on Dr. Barer's appointment, Chairman of the MYOS Board of Directors Robert J. Hariri, M.D., Ph.D., said, "It is a special honor to welcome my long time colleague, friend and mentor, Dr. Barer to the Advisory Board. I consider Sol to be one of the visionary leaders who have helped shape the biotechnology industry, and truly value his insight into our sector's science, marketplace and corporate development."

Dr. Hariri serves as chief executive officer of Celgene Cellular Therapeutics, a division of Celgene Corporation, a position he has held since 2005. Prior to joining Celgene Cellular Therapeutics as president in 2002, Dr. Hariri was founder, chairman and chief scientific officer at Anthrogenesis Corporation/LIFEBANK, Inc., a privately held biomedical technology and service corporation involved in human stem cell therapeutics, which was acquired by Celgene in 2002.

About MYOS CorporationMYOS Corporation is a development stage company focused on the discovery, development and commercialization of therapeutic products that improve muscle health and performance (www.myoscorp.com).

MYOS is the owner of MYO-T12, the world's first clinically demonstrated myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. MYO-T12 is manufactured to optimize biological activity, which MYOS believes has the potential to redefine existing standards of physical health and wellness enhancement. For more information on MYO-T12 and to discover why MYOS is known as "The Muscle Company," visit http://www.MYOT12.com.

Forward-Looking StatementsAny statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the ability to create new products through research and development, the successful launch of Myo-X, the ability to generate the forecasted revenue stream and cash flow from sales of Myo-X, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

See the original post:
MYOS Names Veteran Biotechnology Executive Dr. Sol J. Barer to Chair Scientific Advisory Board

16 May 2012

Angel Biotechnology Holdings plc

("Angel" or "the Company")

Angel signs new contract with ReNeuron to provide GMP (KOSDAQ: 018290.KQ - news) cell manufacturing services for completion of stroke clinical trial

Angel Biotechnology Holdings plc, (AIM:ABH), the biopharmaceutical contract manufacturer, has signed a new contract with ReNeuron Group (Berlin: RQE.BE - news) plc (AIM:RENE) to perform GMP manufacturing services in support of the final part of the PISCES Phase 1 clinical trial of its ReN001 stem cell therapy for stroke; the value of the contract was not disclosed.

Dr Stewart White, Acting CEO, Angel Biotechnology (Berlin: A3G.BE - news) said: "Angel is very proud to be providing ReNeuron with additional manufacturing support to complete this ground breaking Phase 1 clinical trial. This contract is further recognition of the strong partnership between Angel and ReNeuron, and also reaffirms both companies commitment to provide solutions for a real clinical need."

For further information:

Angel Biotechnology Holdings plc

Lorna Peers, Finance Director +44 (0) 131 445 6077

Stewart White, Acting CEO/Commercial Director http://www.angelbio.com

See the original post here:
Angel Biotechnology - Angel signs new contract with ReNeuron

OTTAWA, Ontario--(BUSINESS WIRE)--

David Allan, founding Chairman of YM BioSciences and its 13-year CEO is being recognized by the industry in BIOTECanadas naming him as recipient of the Gold Leaf Award for Industry Leadership. This award is given to an individual who demonstrates exemplary vision and leadership in Canadian biotechnology in a global context. He is being recognized for his commitment to promoting and supporting the growth of biotechnology in Canada.

David Allan has had an important impact on the recognition of Canadian biotechnology internationally with his unwavering commitment about the importance of international public and private capital markets as the lifeblood of the industry, commented Brad Thompson, Chair BIOTECanada. YM BioSciences has demonstrated versatility and resilience, utilizing international partnerships to offset the capital constraints faced by Canadian biotechnology companies. This is a model for many industry colleagues.

During his 17-year involvement with YM the company has enjoyed numerous "firsts" including being the first North American biotechnology company to float its IPO on the London Exchange, which occurred in 2002 simultaneously with listing on the TSX, as well, it is believed, as being the first company outside the United States to receive a Special Protocol Assessment from the FDA. Prior to YM David created the first science and technology-specific investment banking team in Canada to support the capital requirements of the biotechnology industry in the country and creating such novel biotechnology structures as Drug Royalty Corporation as well as YM BioSciences.

"I am thrilled that this 20-year commitment to the industry is being recognised by this exceptional and prestigious award. My commitment to the industry preceded my involvement with YM by being the first in Canada to import, in 1992, the model so successfully established in the United States of biotech-specific investment banks. From that experience came the recognition of the senseless chasm between the billions of dollars spent by our government-level programs supporting basic research and the low enthusiasm of Canadian venture capital funds and public capital markets in Canada to support the conversion of our scientific excellence into medicines useful for human health. I shall continue to work tirelessly, striving to eliminate the established impediments on accessing capital in Canada similarly to a prior successful engagement as Chair the Toronto Stock Exchange's Market Access Committee that created a specific framework encouraging previously unavailable financing of Small and Medium Enterprises through that exchange. I expect that my extensive experience in the management, M&A and financing of biotechnology companies will be useful as a mentor to others and I am delighted to continue broad involvement with the biotechnology industry in Canada as the Chair of YM, Executive Chair of Stem Cell Therapeutics Corp, Lead Director at DiaMedica Inc, and as Chairman of AvidBiologics Inc. in Toronto.

Join us as we celebrate industry leadership during the BIO International Convention at the Boston Convention & Exhibition Center. The Gold Leaf Awards ceremony will take place at the Canada Caf (booth number 735) June 19, 2012 in Boston, MA at 4pm.

More here:
David Allan Lauded for Leadership – Biotechnology Leader Named to Industry Award

Biotechnology is undoubtedly the technology of the future for it not only presents exceptional opportunities, but also gives hope for a better future with better diagnosis and treatment of diseases. In terms of potential and growth, it is not much different from the mystical dragon, and since 2012 is the year of the dragon, it is expected that it would bring in loads of good news and prosperity for this new branch of science.
The good news
For biotechnology, the last year has been strong and monumental with Tax Incentive Legislation being passed in Australia and a very strong and consistent growth in the sector which was recently followed by good news, the Senate Inquiry of the gene patents bill. Since the last year, the Australian Biotechnology has been included amongst the fifth most innovative biotech nations in the world (according to the Scientific American World View). This trend is continuing in the current year, as Australia has shown great potential in developing biotech related agricultural, medical and even environmental research.
The companies of Australian Biotech are confident that the New Year would definitely be the best and until now with tremendous growth in the sector it has proved this. Even the new startup biotech companies in Australia now stand a better chance with the Tax Incentive’s 45% refundable component, even the large corporations would now be able to reduce their R&D expenses by as much as 10%. Such a healthy growth favoring environment has allowed the Australian Biotech companies to make a mark globally and have a steadily rising status even in the competitive markets of US and Europe.
Conclusion
The Australian Biotech industry now needs to revamp itself and embrace a more authentic and transparent management. There should be better communication between the management and the stakeholders. The opportunities are in plenty and the industry environment very supportive, hence the companies should make the most of it and truly let the biotech dragon rise in this year of the dragon.

Source:
http://www.biotechblog.org/rss.xml